(Ceftolozane sulfate + tazobactam sodium) is under clinical development by Merck and currently in Phase II for Febrile Neutropenia. According to GlobalData, Phase II drugs for Febrile Neutropenia have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how (Ceftolozane sulfate + tazobactam sodium)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

(Ceftolozane sulfate + tazobactam sodium) overview

Ceftolozane sulfate and tazobactam sodium (Zerbaxa) is a fixed-dose combination product acts as an anti-infective. It is formulated as a powder for reconstitution solution for intravenous infusion. Zerbaxa is used in combination with metronidazole is indicated for the treatment of complicated intra-abdominal infections caused by the following gram-negative and gram-positive microorganisms: Enterobacter cloacae, Escherichia coli, Klebsiella oxytoca, Klebsiella pneumonia, Proteus mirabilis, Pseudomonas aeruginosa, Bacteroides fragilis, Streptococcus anginosus, Streptococcus constellatus, and Streptococcus salivarius. It is also indicated for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis, cystitis, peritonitis, intraabdominal abscess,cholecystitis, and liver abscess caused by Streptococcus,E. coli, Citrobacter, Klebsiella, Enterobacter, Proteus,and Pseudomonas aeruginos, and for the treatment of hospital-acquired bacterial pneumonia, sepsis, pneumonia caused by serratia and Haemophilus influenzae.

Zerbaxa is under development for the treatment of ventilator-associated bacterial pneumonia. It is also under development for the treatment of complicated intra-abdominal infections, uncomplicated pyelonephritis. It is under development for the treatment of nosocomial pneumonia in pediatric population. It is administered as powder in the from of solution through intravenous route. It was under development for the treatment of hospital acquired pneumonia.

Merck overview

Merck is a biopharmaceutical company focused on the discovery, development, manufacturing and marketing of prescription medicines, biologic therapies, vaccines and animal health products. It offers prescription products for therapy areas related to cardiovascular, cancer, immune disorders, infectious, respiratory and women’s diseases, and diabetes. The company provides animal health products such as vaccines, poultry products, livestock products and aquaculture products. Merck sells medicines to drug wholesalers, retailers, hospitals, government agencies and managed health care providers; and animal health products to veterinarians, distributors and animal producers. The company and its subsidiaries operate in the Americas, Europe, the Middle East, Africa, Asia Pacific, and Latin America. Merck is known as MSD outside the US and Canada and is headquartered in Kenilworth, New Jersey, the US.

For a complete picture of (Ceftolozane sulfate + tazobactam sodium)’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.